HomeAI · summaries
Storia in 8 fonti
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug - Takeda Pharmaceutical Co (NYSE:TAK)
The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit control.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
FDA approves Takeda, Protagonist drug as first treatment for rare blood disorder
FDA approved Takeda & Protagonist's Mimrylo (rusfertide) for polycythemia vera, a rare blood disease.
- ·
morningstar.com
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
